share_log

BMO Capital Maintains Outperform on Candel Therapeutics, Lowers Price Target to $3

Benzinga ·  May 15, 2023 08:31

BMO Capital analyst Evan David Seigerman maintains Candel Therapeutics (NASDAQ:CADL) with a Outperform and lowers the price target from $9 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment